Canaccord Genuity Starts Twist Bioscience (TWST) at Buy With $90 Price Target

Canaccord Genuity analyst Kyle Mikson initiated coverage of Twist Bioscience Corporation (NASDAQ: TWST) with a Buy rating and a $90 price target, adding a fresh institutional endorsement to a stock that already carries a strong consensus from the Street. Shares gained 7.80% on Monday, June 15, 2026, last trading at $82.11.

What Changed

• New coverage initiated: Canaccord Genuity's Kyle Mikson opens on Twist Bioscience with a Buy rating and a $90 price target.
• Target implies upside: The $90 target sits above the June 15 last-traded price of $82.11, which itself exceeded the stock's prior 52-week high of $80.50.
• Expanding coverage universe: Canaccord's initiation adds to a broadening analyst base tracking TWST, with Piper Sandler also recently assigning an Overweight rating, according to supplementary coverage.
• Consensus shift: The latest analyst consensus as of June 1, 2026 stands at 8 Strong Buy, 6 Buy, and 1 Hold, with zero Sell or Strong Sell recommendations, compared to 7 Strong Buy, 7 Buy, and 2 Hold a month earlier.

Why It Matters

Canaccord's initiation is notable in part because the $90 price target was set at a level above the stock's prior 52-week high, signaling a conviction call rather than a routine coverage open. The firm's entry into TWST coverage, alongside the concurrent Piper Sandler Overweight initiation cited in supplementary reports, suggests growing institutional interest in the synthetic biology company's trajectory.

For a stock that has moved from a 52-week low of $23.30 to the current $82.11 level, the analyst community's willingness to set targets above that range reflects expectations that recent business developments, including new antibody deals noted in supplementary coverage, could support continued revenue expansion. Twist Bioscience has posted revenue growth of 19.3% year over year, though the company continues to operate at a net loss.

Wall Street View

The analyst consensus on TWST is firmly constructive. As of June 1, 2026, 14 of 15 analysts carry a Buy-equivalent rating, with not a single Sell or Strong Sell on record. The shift from the prior month's breakdown, which included two Hold ratings, suggests at least one analyst upgraded or initiated at a higher conviction tier. Canaccord's $90 price target and Piper Sandler's Overweight initiation represent the most recent additions to that bullish alignment. The company carries a forward P/E of -84.6x, consistent with a growth-stage biotech still investing ahead of profitability.

Investor Takeaway

Canaccord Genuity's Buy initiation with a $90 price target provides a concrete new data point for investors evaluating TWST after the stock's sharp run from its 52-week low. With 14 of 15 analysts now at Buy-equivalent ratings and two firms initiating coverage within a short window, institutional scrutiny of Twist Bioscience is clearly increasing. Investors should weigh the bullish analyst alignment against the company's ongoing operating losses before drawing conclusions about risk-adjusted positioning.